上皮成長因子受容体(EGFR)変異非小細胞肺癌を含む進行性または転移性固形腫瘍の参加者におけるアミバンタマブの研究 (PALOMA-2)
EGFR 変異非小細胞肺癌を含む進行性または転移性固形腫瘍患者における複数のレジメンでの皮下アミバンタマブの第 2 相非盲検並行コホート研究
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Study Contact
- 電話番号:844-434-4210
- メール:Participate-In-This-Study1@its.jnj.com
研究場所
-
-
California
-
La Jolla、California、アメリカ、92093
- 募集
- University of California at San Diego
-
Orange、California、アメリカ、92868
- 募集
- University of California Irvine
-
Stanford、California、アメリカ、94305
- 募集
- Stanford Cancer Institute
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20016
- 募集
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
-
-
Florida
-
Boca Raton、Florida、アメリカ、33486
- 完了
- Baptist Lynn Cancer Institute
-
Miami Beach、Florida、アメリカ、33140
- 募集
- Mount Sinai Medical Center
-
Orlando、Florida、アメリカ、32804
- 募集
- AdventHealth
-
Tampa、Florida、アメリカ、33612
- 完了
- H. Lee Moffitt Cancer & Research Institute
-
-
Kansas
-
Westwood、Kansas、アメリカ、66205
- 募集
- University of Kansas Cancer Center
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21224
- 募集
- Sidney Kimmel Cancer Center - Bayview Campus
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02118
- 募集
- Boston Medical Center
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School Of Medicine
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- 募集
- Hackensack University Medical Center
-
New Brunswick、New Jersey、アメリカ、08901
- 募集
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
East Syracuse、New York、アメリカ、13057
- 完了
- Hematology-Oncology Associates of CNY
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- 完了
- Novant Health 1
-
Winston-Salem、North Carolina、アメリカ、27106
- 完了
- Novant Health
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- 完了
- Cleveland Clinic
-
Cleveland、Ohio、アメリカ、44111
- 完了
- Cleveland Clinic 1
-
Mayfield Heights、Ohio、アメリカ、44124
- 完了
- Cleveland Clinic 2
-
Warrensville Heights、Ohio、アメリカ、44122
- 完了
- Cleveland Clinic 3
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 完了
- The Huntsman Cancer Institute
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- Virginia Cancer Specialists
-
-
Washington
-
Everett、Washington、アメリカ、98201
- 完了
- Providence Regional Cancer Partnership
-
Seattle、Washington、アメリカ、98104
- 募集
- Swedish Cancer Institute
-
Seattle、Washington、アメリカ、98101
- 完了
- Virginia Mason Medical Center
-
-
-
-
-
Cheltenham、イギリス、GL53 7AN
- 完了
- Cheltenham General Hospital
-
Devon、イギリス、TQ2 7AA
- 募集
- Torbay Hospital-Devon
-
Edinburgh、イギリス、EH4 2XU
- 募集
- Edinburgh Cancer Centre Western General
-
Leicester、イギリス、LE1 5WW
- 募集
- Leicester Royal Infirmary
-
London、イギリス、NW1 2PG
- 募集
- University College London Hospitals
-
Nottingham、イギリス、NG5 1PB
- 募集
- Nottingham City Hospital
-
Portsmouth、イギリス、PO6 3LY
- 募集
- Queen Alexandra Hospital
-
-
-
-
-
Haifa、イスラエル、3109601
- 募集
- Rambam Medical Center
-
Jerusalem、イスラエル、9103102
- 募集
- Shaare Zedek Medical Center
-
Kfar Saba、イスラエル、44281
- 完了
- Meir Medical Center
-
Petah Tikva、イスラエル、4941492
- 募集
- Rabin Medical Center
-
Ramat Gan、イスラエル、52621
- 募集
- Sheba Medical Center
-
-
-
-
-
Genova、イタリア、16132
- 募集
- Policlinico Hospital San Martino- IRCCS for Oncology
-
Milan、イタリア、20132
- 募集
- Ospedale San Raffaele
-
Milan、イタリア、20162
- 募集
- ASST Grande Ospedale Metropolitano Niguarda
-
Monza、イタリア、20090
- 募集
- Azienda Ospedaliera San Gerardo
-
Naples、イタリア、80131
- 募集
- Azienda Ospedaliera Specialistica dei Colli
-
-
-
-
-
A Coruña、スペイン、15006
- 募集
- Hosp Univ A Coruna
-
Alicante、スペイン、03010
- 募集
- General University Hospital of Alicantet
-
Barcelona、スペイン、08025
- 募集
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona、スペイン、08003
- 募集
- Hosp. Del Mar
-
Barcelona、スペイン、8908
- 募集
- Inst. Cat. Doncologia-H Duran I Reynals
-
Barcelona、スペイン、08035
- 募集
- Hosp Univ Vall D Hebron
-
Madrid、スペイン、28034
- 募集
- Hosp. Univ. Ramon Y Cajal
-
Madrid、スペイン、28041
- 募集
- Hosp. Univ. 12 de Octubre
-
Madrid、スペイン、28046
- 募集
- Hosp. Univ. La Paz
-
Madrid、スペイン、28007
- 募集
- Hosp. Gral. Univ. Gregorio Maranon
-
Málaga、スペイン、29010
- 募集
- Hosp Regional Univ de Malaga
-
Seville、スペイン、41009
- 募集
- Hosp. Virgen Macarena
-
Valencia、スペイン、46010
- 募集
- Hosp. Clinico Univ. de Valencia
-
Valencia、スペイン、46014
- 募集
- Hosp. Gral. Univ. Valencia
-
-
-
-
-
Berlin、ドイツ、13125
- 完了
- Evangelische Lungenklinik Berlin
-
Cologne、ドイツ、50937
- 募集
- Universitaetsklinikum Koeln
-
Grosshandorf、ドイツ、22927
- 募集
- LungenClinic Grosshansdorf GmbH
-
Immenhausen、ドイツ、34376
- 募集
- Lungenfachklinik Immenhausen
-
Würzburg、ドイツ、97074
- 募集
- Klinikum Würzburg Mitte gGmbH Standort Missioklinik
-
-
-
-
-
Caen、フランス、14076
- 募集
- Centre Francois Baclesse
-
Dijon、フランス、21079
- 完了
- Centre Georges-François Leclerc
-
Nîmes、フランス、30029
- 募集
- Institut de Cancérologie du Gard
-
Paris、フランス、75248
- 募集
- Institut Curie
-
Saint-Herblain、フランス、44805
- 募集
- Institut de cancerologie de l'ouest
-
Villejuif、フランス、94800
- 募集
- Gustave Roussy
-
-
-
-
-
Barretos、ブラジル、14784-400
- 募集
- Fundacao Pio XII
-
Belo Horizonte、ブラジル、30130 090
- 募集
- PERSONAL Oncologia de Precisao e Personalizada
-
Londrina、ブラジル、86015 520
- 募集
- Hospital do Cancer de Londrina
-
Porto Alegre、ブラジル、90035-001
- 募集
- Hospital Moinhos de Vento
-
Rio de Janeiro、ブラジル、22281 100
- 募集
- IDOR - Regional Rio de Janeiro
-
Salvador、ブラジル、41253-190
- 募集
- IDOR - Regional Bahia
-
São Paulo、ブラジル、01509 900
- 募集
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、ブラジル、01327 001
- 募集
- Hospital Alemao Oswaldo Cruz
-
São Paulo、ブラジル、01409-001
- 完了
- Impar Servicos Hospitalares SA Hospital Nove de Julho
-
-
-
-
-
Kuala Lumpur、マレーシア、59100
- 募集
- University Malaya Medical Centre
-
Kuantan、マレーシア、25100
- 募集
- Hospital Tengku Ampuan Afzan
-
Kuching、マレーシア、93586
- 募集
- Hospital Umum Sarawak
-
Petaling Jaya、マレーシア、46050
- 募集
- Beacon Hospital Sdn Bhd
-
-
-
-
-
Baoding、中国、071051
- 完了
- Affiliated Hospital of Hebei University
-
Changchun、中国、130000
- 募集
- Jilin cancer hospital
-
Chengdu、中国、610041
- 募集
- Sichuan Cancer Hospital
-
Chengdu、中国、610047
- 募集
- West China Hospital Sichuan University
-
Chongqing、中国、400038
- 募集
- The First Affiliated Hospital of PLA Army Medical University
-
Guangzhou、中国、510060
- 募集
- The First Affiliated Hospital Sun Yat sen University
-
Hangzhou、中国、310003
- 募集
- The First Affiliated Hospital Zhejiang University College of Medicine
-
Hangzhou、中国、310016
- 募集
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Harbin、中国、150000
- 募集
- Harbin medical university cancer hospital
-
Huizhou、中国、516001
- 募集
- Huizhou Municipal Central Hospital
-
Liuzhou、中国、545006
- 完了
- Liuzhou people's Hospital
-
Shanghai、中国、200032
- 募集
- Fudan University Shanghai Cancer Center
-
Tianjin、中国、300052
- 募集
- Tianjin Medical University General Hospital
-
Wenzhou、中国、325000
- 募集
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan、中国、430022
- 募集
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology
-
Wuxi、中国、214122
- 完了
- Hospital of Jiangnan University
-
Xi'an、中国、710061
- 募集
- The First Affiliated Hospital of Xian Jiaotong University
-
Yantai、中国、264000
- 完了
- Yantai Yuhuangding Hospital
-
-
-
-
-
Himeji、日本、670-8520
- 積極的、募集していない
- National Hospital Organization Himeji Medical Center
-
Matsusaka、日本、515 8544
- 積極的、募集していない
- Saiseikai Matsusaka Municipal Hospital
-
Niigata、日本、951-8566
- 積極的、募集していない
- Niigata Cancer Center Hospital
-
Shizuoka、日本、411 8777
- 積極的、募集していない
- Shizuoka Cancer Center
-
Tokyo、日本、135 8550
- 積極的、募集していない
- The Cancer Institute Hospital of JFCR
-
Wakayama、日本、641 8510
- 積極的、募集していない
- Wakayama Medical University Hospital
-
-
-
-
-
Goyang-si、韓国、10408
- 募集
- National Cancer Center
-
Seongnam-si、韓国、13620
- 募集
- Seoul National University Bundang Hospital
-
Seoul、韓国、03080
- 募集
- Seoul National University Hospital
-
Seoul、韓国、03722
- 募集
- Severance Hospital Yonsei University Health System
-
Seoul、韓国、05505
- 完了
- Asan Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-small cell lung cancer (NSCLC) that is not amenable to curative therapy including surgical resection or chemoradiation. Additional Cohort specific disease requirements include: Cohorts 1, 3, 3b, 5, 6 and 7: epidermal growth factor receptor (EGFR) exon 19 deletion (Exon19del) or Exon 21 L858R mutation; Cohort 2: EGFR Exon 20ins mutation. Cohorts 1,5,and6: Participant should not have received any prior systemic therapy for locally advanced or metastatic NSCLC. Cohort 2: Participant should not have received any prior systemic therapy for locally advanced or metastatic NSCLC. Cohorts 3and3b: Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second-line setting after prior treatment with first- or second-generation EGFR tyrosine kinase inhibitor (TKI) as a monotherapy. Cohort 4: Participants need to currently be on an amivantamab IV Q2W regimen (1,050 mg or 1,400 mg depending on weight) for at least 8 weeks, as part of standard of care, an expanded access program, or as a rollover from a long-term extension, without any amivantamab dose reduction. Cohort 7: Participants must have progressed on or after the combination of amivantamab and lazertinib as the most recent line of treatment. The combination of amivantamab and lazertinib must have been administered as the first-line treatment for locally advanced or metastatic disease. Cohort 2, 3, 3b, and 7 only: Squamous NSCLC are excluded. EGFR mutation must have been identified as determined by Food and Drug Administration (FDA) approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states [US]) or an accredited local laboratory (sites outside of the US). A copy of the initial test report documenting the EGFR mutation must be included in the participant records and a deidentified copy must also be submitted to the sponsor
- All cohorts except Cohort 4: Participants must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. If the only target lesion has been previously irradiated, it must show signs of disease progression since radiation was completed If only 1 non-irradiated measurable lesion exists, which undergoes a biopsy and is acceptable as a target lesion, the baseline tumor assessment scans should be performed at least 14 days after the biopsy
- May have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Have adequate organ (renal, hepatic, hematological, coagulation and cardiac) functions
- Participant must have eastern cooperative oncology group (ECOG) status of 0 or 1
- Cohort 6: Must be eligible for, and agree to comply with, the use of prophylactic anticoagulation with a direct oral anticoagulant or a low molecular weight heparin during the first 4 months of study treatment
- A participant must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 6 months after receiving the last dose of study treatment. Participants with child bearing potential should consider preservation of eggs prior to study treatment as anti-cancer treatments may impair fertility
Exclusion Criteria:
- Participant has a medical history of interstitial lung disease (ILD), including drug induced ILD or radiation pneumonitis
- Participant has a history of hypersensitivity to any excipients of the investigational products to be used in their enrollment cohort
- Participant has received a live or live attenuated vaccine within 3 months before Cycle 1 Day 1. The seasonal influenza vaccine and non-live vaccines against Coronavirus disease 19 (COVID-19) are not exclusionary
- For all cohorts (with regimens potentially including lazertinib): Participant is currently receiving medications or herbal supplements known to be potent Cytochrome (CYP3A4/5) inducers and is unable to stop use for an appropriate washout period prior to Cycle 1 Day 1
- Other clinically active liver disease of infectious origin
- Participant has a history of clinically significant cardiovascular disease including, but not limited to: a) All cohorts: diagnosis of deep vein thrombosis or pulmonary embolism within 1 month prior to the first dose of study treatment(s), or any of the following within 6 months prior to the first dose of study treatment(s): myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary; b) All cohorts (with regimens potentially including lazertinib): Participant has a significant genetic predisposition to venous thromboembolic events (VTE; such as Factor V Leiden); c) All cohorts (with regimens potentially including lazertinib): Participant has a prior history of VTE and is not on appropriate therapeutic anticoagulation as per NCCN or local guidelines; d) prolonged corrected QT interval by Fridericia (QTcF) interval greater than (>) 480 milliseconds (msec) or clinically significant cardiac arrhythmia or electrophysiologic disease (example, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate); e) uncontrolled (persistent) hypertension: systolic blood pressure >160 millimeter(s) of mercury (mmHg); diastolic blood pressure >100 mmHg; f) Congestive heart failure defined as NYHA class III-IV or hospitalization for congestive heart failure (CHF) (any New York Heart Association [NYHA] class) within 6 months of treatment initiation at Cycle 1/day 1 (C1D1); g) pericarditis/clinically significant pericardial effusion; h) myocarditis; i) baseline left ventricular ejection fraction (LVEF) below the institution's lower limit of normal at screening, as assessed by echocardiogram or multigated acquisition (MUGA) scan
- Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants who have received definitive radiation or surgical treatment for symptomatic or unstable brain metastases and have been clinically stable and asymptomatic for at least 2 weeks before Screening are eligible, provided they have been either off corticosteroid treatment or are receiving low-dose corticosteroid treatment (less than or equal to [<=] 10 milligrams per day [mg/day] prednisone or equivalent) for at least 2 weeks prior to treatment allocation
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort 1(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q2W) + Lazertinib
Participants with treatment-naive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) exon 19 deletion (exon19del) or exon 21 leucine 858 to arginine substitution (exon 21 L858R) mutation, will receive amivantamab SC-CF injection, 1600 milligrams (mg) or 2240 mg if body weight is greater than or equal to (>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily. Eligible participants will be given an option to enter long-term extension (LTE) phase and may continue to receive access to study treatment(s) within the study by transferring to the Drug Access (DA)-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
他の名前:
Lazertinib will be administered as an oral tablet.
他の名前:
|
|
実験的:Cohort 2(Exon20 NSCLC,1L, Previously Untreated): Amivantamab (Q3W) + Chemotherapy
Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR exon20ins mutation will receive Amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle, starting with Cycle 2 along with pemetrexed 500 milligrams per meter square (mg/m^2) as intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and IV infusion carboplatin area under the concentration-time curve 5 milligrams per milliliters (mg/mL) per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
他の名前:
Carboplatin will be administrated by IV infusion. Pemetrexed will be administered by IV infusion. |
|
実験的:Cohort 3(Exon19del/Exon21 L858R NSCLC,2L,Post Osimertinib):Amivantamab(Q3W)+Lazertinib+Chemotherapy
Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Lazertinib 240 mg orally once daily starting Cycle 5 Day 1 when carboplatin is complete or sooner if carboplatin discontinued earlier than Cycle 4. Eligible participants will be given an option to enter LTE phase and DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
他の名前:
Lazertinib will be administered as an oral tablet.
他の名前:
Carboplatin will be administrated by IV infusion. Pemetrexed will be administered by IV infusion. |
|
実験的:Cohort 3b(Exon19del/Exon21 L858R NSCLC, 2L, Post Osimertinib): Amivantamab (Q3W)+Chemotherapy
Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
他の名前:
Carboplatin will be administrated by IV infusion. Pemetrexed will be administered by IV infusion. |
|
実験的:Cohort 4(Previously Treated with Amivantamab IV): Switch from Amivantamab IV to SC-CF (Q2W)
Participants who were previously on amivantamab IV once every 2 weeks (Q2W) regimen as part of standard of care, for at least 8 weeks, either as monotherapy or combination with lazertinib, will receive amivantamab SC-CF injection 1600 mg and 2240 mg if body weight is greater than or equal to 80 kg. Participants who continue to benefit from study treatments, as determined by their investigator, may shift to the drug access (DA)-LTE phase. |
Amivantamab will be administered subcutaneously by manual injection.
他の名前:
Lazertinib will be administered as an oral tablet.
他の名前:
|
|
実験的:Cohort 5(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q4W) + Lazertinib
Participants with treatment-naïve locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation will receive amivantamab SC-CF induction with 1,600 mg (or 2,240 mg if BW >=80 kg) on Cycle 1 Days 1, 8, 15, and 22, starting with Cycle 2 on Day 1 of each next 28-day cycle, amivantamab SC-CF (160 mg/mL co-formulated with rHuPH20) by manual injection at 3,520 mg (or 4,640 mg if BW >=80 kg); along with lazertinib 240 mg by mouth once daily from Cycle 1 Day 1. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
他の名前:
Lazertinib will be administered as an oral tablet.
他の名前:
|
|
実験的:Cohort6(Exon19del/Exon21L858R,NSCLC1L,PreviouslyUntreated):Amivantamab(Q2W)+Lazertinib+Anticoagulant
Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation treated will receive will receive amivantamab SC-CF injection, 1600 milligrams (mg) and 2240 mg if body weight is greater than or equal to (>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily from Cycle 1 Day 1. Participants will additionally take prophylactic anticoagulation with a direct oral anticoagulant (DOAC) or a low molecular weight heparin (LMWH) for the first four months of study treatment (from Day 1 through Day 120) with the combination of amivantamab and lazertinib. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
他の名前:
Lazertinib will be administered as an oral tablet.
他の名前:
DOAC will be administered orally. LMWH will be administered subcutaneously. |
|
実験的:Cohort 7(Exon19del/Exon21 L858R NSCLC,2L,Post Amivantamab+Lazertinib):Amivantamab(Q3W)+Chemotherapy
Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after the combination of amivantamab and lazertinib will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
Amivantamab will be administered subcutaneously by manual injection.
他の名前:
Carboplatin will be administrated by IV infusion. Pemetrexed will be administered by IV infusion. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All Cohorts Except Cohort 4: Objective Response Rate (ORR) Based on Investigator Assessment (INV)
時間枠:Up to 1 year 6 months
|
ORR based on INV will be reported. ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by investigator. |
Up to 1 year 6 months
|
|
Cohort 4: Number of Participants with Adverse Events (AEs)
時間枠:Up to approximately 4 years and 9 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. |
Up to approximately 4 years and 9 months
|
|
Cohort 4: Number of Participants with AEs by Severity
時間枠:Up to approximately 4 years and 9 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to approximately 4 years and 9 months
|
|
Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values
時間枠:Up to approximately 4 years and 9 months
|
Number of participants with abnormalities in clinical laboratory values (which includes serum chemistry, hematology, coagulation, urinalysis, and serology) will be reported. |
Up to approximately 4 years and 9 months
|
|
Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity
時間枠:Up to approximately 4 years and 9 months
|
Number of participants with laboratory values abnormalities which includes serum chemistry, hematology, coagulation, urinalysis, and serology) by severity will be reported. Severity of laboratory values abnormalities will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to approximately 4 years and 9 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All Cohorts Except Cohort 4: Number of Participants with AEs
時間枠:Up to 1 year 6 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Number of Participants with AEs by Severity
時間枠:Up to 1 year 6 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values
時間枠:Up to 1 year 6 months
|
Number of participants with abnormalities in clinical laboratory values (which includes serum chemistry, hematology, coagulation, urinalysis, and serology) will be reported. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity
時間枠:Up to 1 year 6 months
|
Number of participants with abnormalities in clinical laboratory values which includes serum chemistry, hematology, coagulation, urinalysis, and serology) by severity will be reported. Severity of laboratory values abnormalities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: ORR Based on Independent Central Review (ICR)
時間枠:Up to 1 year 6 months
|
ORR based on ICR will be reported. The ORR is defined as the percentage of participants who achieve a CR or PR, based on RECIST version 1.1, as confirmed by ICR. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Duration of Response (DoR) Based on Investigator Assessment (INV)
時間枠:Up to 1 year 6 months
|
DoR based on INV is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Time to Response (TTR) Based on INV
時間枠:Up to 1 year 6 months
|
TTR (that is, time to first response) based on INV is defined as the time from the first dose of study treatment to the date of first documentation of a response (PR or CR) prior to any disease progression and subsequent anticancer therapy, based on RECIST version 1.1., for participants who have PR or CR as their best response. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Clinical Benefit Rate (CBR)
時間枠:Up to 1 year 6 months
|
CBR is defined as the percentage of participants achieving CR or PR, or durable standard deviation (SD) of a duration of at least 11 weeks as defined by RECIST version 1.1. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Progression-free Survival (PFS)
時間枠:Up to 3 years
|
The PFS is defined as the time from the first dose of study treatment until the date of objective disease progression or death, whichever comes first, based on RECIST version 1.1. |
Up to 3 years
|
|
All Cohorts Except Cohort 4: Overall Survival (OS)
時間枠:Up to approximately 4 years
|
The OS is defined as the time from the first dose of study treatment until the date of death due to any cause. |
Up to approximately 4 years
|
|
All Cohorts Except Cohort 4: Number of Participants with Venous Thromboembolic Events (VTE)
時間枠:Up to 1 year 6 months
|
Number of participants with adverse events of VTE (pulmonary embolism and deep vein thrombosis) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Number of Participants with Venous Thromboembolic Events (VTE) by Severity
時間枠:Up to 1 year 6 months
|
Number of participants with adverse events of VTE (pulmonary embolism and deep vein thrombosis) by severity will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). |
Up to 1 year 6 months
|
|
All Cohorts Except Cohort 4: Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough) of Amivantamab
時間枠:Cycle 2 Day 1 of 28-day cycle
|
Ctrough is defined as the serum concentration of amivantamab immediately prior to the next drug administration. |
Cycle 2 Day 1 of 28-day cycle
|
|
Cohort 4: Cancer Therapy Satisfaction as Assessed by Modified Therapy Administration Satisfaction Questionnaire - Intravenous (TASQ-IV)
時間枠:Up to 1 year 6 months
|
Patient-reported outcome (PRO): Cancer therapy satisfaction will be assessed using the modified TASQ-IV. The modified TASQ is a 12-item questionnaire measuring the impact of each mode of treatment administration on five domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each of the domain/scale scores is scored on a 1-100 scale, where 0 is worst and 100 is best. |
Up to 1 year 6 months
|
|
Cohort 4: Cancer Therapy Satisfaction as Assessed by Modified Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC)
時間枠:Up to 1 year 6 months
|
PRO: Cancer therapy satisfaction will be assessed using the modified TASQ-SC. The modified TASQ is a 12-item questionnaire measuring the impact of each mode of treatment administration on five domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each of the domain/scale scores is scored on a 1-100 scale, where 0 is worst and 100 is best. |
Up to 1 year 6 months
|
|
Cohort 4: Patient-reported Status as Assessed by Patient Global Impression of Change (PGIC) Scale Score
時間枠:Up to 1 year 6 months
|
Patient-reported status as assessed by PGIC scale score will be reported. The PGIC is an assessment of the participant's overall sense of whether there has been a change since starting treatment. The PGIC is a 7-point response scale. Participants will be asked to rate their current fatigue as compared to when they started the study, using the following 7-point scale: 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, and 7 = Much worse. |
Up to 1 year 6 months
|
|
Cohort 4: Patient-reported Status as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score
時間枠:Up to 1 year 6 months
|
Patient-reported status as assessed by PGIS scale score will be reported. The PGIS is an assessment of lung cancer severity at a given point in time. The PGIS is a 5-point response scale. Participants will be asked to rate their fatigue over the past 7 days using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe. |
Up to 1 year 6 months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CR109264
- 2022-000526-21 (EudraCT番号)
- 61186372NSC2002 (その他の識別子:Janssen Research & Development, LLC)
- 2023-505065-91-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。